Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Exelixis Inc patents


Recent patent applications related to Exelixis Inc. Exelixis Inc is listed as an Agent/Assignee. Note: Exelixis Inc may have other listings under different names/spellings. We're not affiliated with Exelixis Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Exelixis Inc-related inventors


Malate salt of n-(4-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

Disclosed are malate salts of n-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (l)-malate salt, a (d)-malate salt, a (dl) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.. ... Exelixis Inc

Malate salt of n-(4-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

Disclosed are malate salts of n-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (l)-malate salt, a (dl) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide.. ... Exelixis Inc

C-met modulators and methods of use

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-met, kdr, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. ... Exelixis Inc

Malate salt of n-(4-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

. . Disclosed are malate salts of n-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (l)-malate salt, a (d)-malate salt, a (dl) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.. ... Exelixis Inc

C-met modulator pharmaceutical compositions

Pharmaceutical compositions and unit dosage forms comprising compound i are disclosed.. . ... Exelixis Inc

Inhibitors of pi3k-delta and methods of their use and manufacture

The invention is directed to compounds of formula i: and pharmaceutically acceptable salts or solvates thereof as well as methods of making and using the compounds.. . ... Exelixis Inc

Drug combinations to treat multiple myeloma

This invention relates to the combination of a c-met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.. . ... Exelixis Inc

Drug combination to treat melanoma

This invention relates to the combination of vemurafenib and the heat shock protein 90 (hsp90) inhibitor xl888 to treat melanoma, particularly braf v600 mutant melanoma in patients in need of such treatment.. . ... Exelixis Inc

Method of preparing fluorine-18 labeled cabozantinib and its analogs

The present invention relates to a method of preparing cabozantinib (cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18f labeled cabozantinib.. . ... Exelixis Inc

Dosing of cabozantinib formulations

The invention relates to administration of various pharmaceutical formulations of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.. . ... Exelixis Inc

Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds

The present invention is directed to processes for making and compositions containing quinolines such as formula i or pharmaceutically acceptable salts thereof wherein: x1 is h, br, cl, or x2 is h, br, cl, or n1 is 1-2; and n2 is 1-2.. . ... Exelixis Inc

Crystalline solid forms of n--n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

The invention relates to novel crystalline solid forms of the chemical compound n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. ... Exelixis Inc

Method of treating lung adenocarcinoma

This invention is directed to the treatment of cancer in a patient, particularly a patient with lung adenocarcinoma, and more particularly a patient with slc34a2-ros1, cd74-ros1, or fig-ros1 fusion-positive non-small cell lung cancer, with an inhibitor of met, vegfr2, and ros1 which is a compound of formula (i): or a pharmaceutically acceptable salt thereof.. . ... Exelixis Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Exelixis Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Exelixis Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###